Computational platform company focused on transforming drug discovery and materials science.
Schrödinger, Inc., along with its subsidiaries, specializes in providing a cutting-edge physics-based software platform tailored for the discovery of novel molecules used in drug development and materials applications. The company operates through two distinct segments: Software and Drug Discovery. The Software segment primarily focuses on licensing its advanced software tools to support drug discovery efforts within the life sciences and materials science industries.
In addition to its software offerings, Schrödinger, Inc. actively engages in Drug Discovery through the development of a robust portfolio of preclinical and clinical programs. This segment emphasizes both internal research initiatives and strategic collaborations aimed at advancing innovative therapeutic candidates.
The company's clientele spans a diverse spectrum, including biopharmaceutical firms, industrial companies, academic institutions, and government laboratories worldwide. By leveraging its sophisticated software solutions and expertise in molecular simulations, Schrödinger supports its partners in accelerating the discovery and optimization of molecules with potential applications across various fields.
Established in 1990 and headquartered in New York, New York, Schrödinger, Inc. continues to drive innovation in computational chemistry and molecular modeling. With a steadfast commitment to advancing scientific research and development, the company remains at the forefront of enabling transformative discoveries that address complex challenges in drug development and materials science.